浙江海擘生物

Hyper Biotech is a biopharmaceutical company headquartered in Hangzhou, China, specializing in the development of innovative small molecule drugs for challenging therapeutic targets. The company utilizes its proprietary Hyper-Covalent technology platform to design and optimize covalent inhibitors and molecular glues, specifically targeting undruggable proteins. Their research and development efforts are primarily focused on oncology, with a pipeline that includes programs targeting KRAS mutations and synthetic lethality targets like WRN. Hyper Biotech is backed by prominent venture capital firms and aims to provide transformative treatments for patients with solid tumors and other serious diseases.